November 5, 2020 -- Artificial intelligence (AI) firm Iktos plans to collaborate with pharmaceutical giant Merck on AI for new drug design.
The partnership will allow Merck to use Iktos' generative design technology to develop a drug discovery program. Iktos' software creates virtual novel molecules for treating particular diseases. The company markets its AI technology as both services and software, it said; its AI software as a service (SaaS) software is called Makya and its AI SaaS platform, Spaya.